Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
37.05 USD | +5.14% | +16.77% | +25.25% |
04-29 | Wells Fargo Upgrades Tandem Diabetes Care to Overweight From Equalweight, Price Target is $45 | MT |
04-26 | North American Morning Briefing : Tech Still in -2- | DJ |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- Low profitability weakens the company.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+25.25% | 2.39B | B | ||
-2.54% | 186B | C+ | ||
-1.85% | 107B | C | ||
-4.26% | 67.44B | A | ||
+1.39% | 50.03B | B- | ||
+16.82% | 47.81B | B- | ||
+5.33% | 41.03B | B+ | ||
+3.49% | 26.85B | B | ||
+0.65% | 25.82B | A- | ||
+17.22% | 24.74B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- TNDM Stock
- Ratings Tandem Diabetes Care, Inc.